Two treatments tested in Michigan Medicine clinical trials have received FDA approval, expanding options for people with precursor and relapsed multiple myeloma. In a Q&A, Rogel Cancer Center’s Matthew Pianko discusses how the therapies work and how researchers are using genetics and risk profiling to better understand disease progression.
